Jianhua Zhou1, James Sun2, Harrison Xiao Bai3, Xiangyan Huang4, Yingjie Zou4, Xia Tan4, Zishu Zhang5, Xiangqi Tang4, Yongguang Tao6, Bo Xiao7, Paul J Zhang2, Li Yang4. 1. Department of Pathology, First Xiangya Hospital, Central South University, Changsha, Hunan, China. 2. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 5. Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 6. Cancer Research Institute of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. 7. Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract
BACKGROUND: The low incidence of spinal chordoma precludes a prospective study of prognostic factors with a large patient cohort. OBJECTIVE: To perform a comprehensive integrative analysis on the prognostic factors, treatment, and outcomes of patients with spinal chordoma using data from 2 institutions and the literature. METHODS: Appropriate studies were identified per search criteria. The local database was retrospectively searched to include a similar patient cohort. RESULTS: Overall, 108 studies from the literature and 30 patients from our local institution were identified, resulting in a total of 682 patients. The median age was 57 years old and 35.2% were female. The median follow-up was 46 months (range: 1-408). The median progression-free survival (PFS) and overall survival (OS) were 72 months and 115 months, respectively. Significant prognostic factors for PFS on multivariate analysis included age (pediatric vs adult, hazard ratio [HR]: 2.00-14.36), tumor location (mobile spine vs sacral spine, HR: 0.31-0.87), pathology (differentiated vs classic, HR: 2.48-10.90),and chemotherapy (HR:1.11-3.85). Significant prognostic factors for OS on multivariate analysis included age (geriatric vs adult, HR: 1.52-3.45 and pediatric vs adult, HR: 1.73-9.36), bladder or bowel dysfunction (HR: 1.27-5.43), pathology (dedifferentiated vs classic, HR: 2.38-11.09), recurrence or progression (HR: 1.72-4.48), and metastases (HR: 1.11-2.47). CONCLUSION: In patients with spinal chordoma, young age, location in sacral spine, dedifferentiated pathology, and chemotherapy were negative predictors of PFS, while young and old age, bladder or bowel dysfunction at presentation, dedifferentiated pathology, recurrence or progression, and metastases portended a worse OS.
BACKGROUND: The low incidence of spinal chordoma precludes a prospective study of prognostic factors with a large patient cohort. OBJECTIVE: To perform a comprehensive integrative analysis on the prognostic factors, treatment, and outcomes of patients with spinal chordoma using data from 2 institutions and the literature. METHODS: Appropriate studies were identified per search criteria. The local database was retrospectively searched to include a similar patient cohort. RESULTS: Overall, 108 studies from the literature and 30 patients from our local institution were identified, resulting in a total of 682 patients. The median age was 57 years old and 35.2% were female. The median follow-up was 46 months (range: 1-408). The median progression-free survival (PFS) and overall survival (OS) were 72 months and 115 months, respectively. Significant prognostic factors for PFS on multivariate analysis included age (pediatric vs adult, hazard ratio [HR]: 2.00-14.36), tumor location (mobile spine vs sacral spine, HR: 0.31-0.87), pathology (differentiated vs classic, HR: 2.48-10.90),and chemotherapy (HR:1.11-3.85). Significant prognostic factors for OS on multivariate analysis included age (geriatric vs adult, HR: 1.52-3.45 and pediatric vs adult, HR: 1.73-9.36), bladder or bowel dysfunction (HR: 1.27-5.43), pathology (dedifferentiated vs classic, HR: 2.38-11.09), recurrence or progression (HR: 1.72-4.48), and metastases (HR: 1.11-2.47). CONCLUSION: In patients with spinal chordoma, young age, location in sacral spine, dedifferentiated pathology, and chemotherapy were negative predictors of PFS, while young and old age, bladder or bowel dysfunction at presentation, dedifferentiated pathology, recurrence or progression, and metastases portended a worse OS.
Authors: Johannes Goldberg; Simon Heinrich Bayerl; Christian Witzel; Felix Aigner; Christopher P Ames; Peter Vajkoczy Journal: Neurosurg Rev Date: 2019-11-18 Impact factor: 3.042
Authors: Redwan Jabbar; Jakub Jankowski; Agnieszka Pawełczyk; Bartosz Szmyd; Julia Solek; Olaf Pierzak; Maciej Wojdyn; Maciej Radek Journal: J Clin Med Date: 2022-07-15 Impact factor: 4.964
Authors: Jeffrey I Traylor; Mark N Pernik; Aaron R Plitt; Michael Lim; Tomas Garzon-Muvdi Journal: Cancers (Basel) Date: 2021-05-17 Impact factor: 6.639